Background. Avascular necrosis of the femoral head (ANFH) is a disabling disease that often leads to hip replacement. However, due to the increasing incidence among the young population, various methods of organ-preserving treatment have been proposed aimed at slowing the progression of ANFH and preserving the function of the hip joint. Today, the procedure for introducing mesenchymal cells into the focus of osteonecrosis causes a lot of controversy and disagreement, which is the subject of discussion in our review. Aim of the study: a non-systematic analysis of the accumulated literature data on the effectiveness, safety, advantages and disadvantages of treating patients with early stages of avascular necrosis of the femoral head using the tunneling method using multipotent mesenchymal cells, as well as their impact on reducing the risk of disease progression and long-term treatment results. Material and Methods. A 10-year literature search (2013-2023) was conducted in the PubMed, Scopus and eLIBRARY databases. According to our inclusion criteria, the review included 8 high-quality studies that used mesenchymal cells to treat ANFH. Results. We analyzed 548 hips from 8 studies based on our inclusion and non-inclusion criteria. The mean follow-up period was from 24 to 360 months. In most cases, functional indicators improved. Radiological progression to the next stage occurred in 31.25% of cases and the need for hip arthroplasty was 30.6% in the group where mesenchymal cells were used. Conclusion. The use of multipotent mesenchymal cells in the complex treatment of ANFH in the early (I, II according to ARCO) stages of ANFH can improve the function of the hip joint, slow down the progression of the disease and reduce the need for hip arthroplasty.
Read full abstract